GLENMARK

PHARMACEUTICALS LTD.

By- SURAJ
WARTHY
9110
B

INTRODUCTION

Founded- in 1977
Founder- Mr. Gracias Saldanha
Headquartered- Mumbai, India
Industry-Pharmaceuticals Drug &Healthcare
Traded as BSE: 532296 NSE: GLENMARK
Key people-Glenn Saldanha, MD & CEO
Products- Medicines and Vaccines
Revenue- Glen mark's consolidated revenue increases by 18.98% to Rs.
12,378.82 Mn for Q1 FY 13-14
Employees-7,000
Subsidiaries- Glenmark Generics Ltd.

GLENMARKS BUSINESS INTO TWO CATEGORIES-

SPECIALITY BUSINESS AND GLENMARK GENERICS LTD.

Glenmark branded generics 5 regions Asia including India, Central Eastern Europe, Africa, Latin
America and CIS.
Glenmark has established itself among the top 25 generics companies in the US and also built a
sizeable API business in a short period.

Formulation business, its business spans segments such asDermatology

Internal Medicine
Paediatrics
Gynaecology
ENT and Diabetes.

The company's business in Africa and Middle East markets -:

GLENMARK launched new products showing 40 % increase in 2012-13
PRODUCT

COUNTRY

Supiroban

south Africa

Flexilor

Kenya

Glimulin

UAE

API segments global generic players-:

The business continues its leadership position for

Lercandipine

Topiramate

Amiodarone

TOP 5 MAJOR COMPETITORS OF GLENMARK

SUN PHARMA

DR.REDDYS
LAB

LUPIN

CIPLA

GLAXOSMITHKLINE

Glenmarks current portfolio consists of 83 products authorized for distribution in the U.S. market .
46 ANDAs pending approval with the U.S. FDA.

STRENGTH-

WEAKNESS-

Extremely productive R&D efforts.

Strong NCE pipeline with three
compounds in Phase II clinical trials.

Currency appreciation as exp

contributes 55% of Glenmarks
revenues (excluding license fees)

Built-up skills in NCE research over

last 6 years.

Negligible presence in the European

Markets.

Built-up strong franchises in the US

generic market in a short duration.

OPPORTUNITY-

THREATS-

Re-negotiation of GRC-8200 with

another partners.

Risk of failure/ delays in NCE research.

Focus on Biologics research ~ huge

potential going forward.
A pipeline of 11 compounds comprising
of 6 NCEs and 5 NBEs.

Acquisition and integration risk.

Pricing pressure in the regulated
generic markets.
Execution risk in the base business.

STRATEGY
TARGET 2015
Global end-to-end Specialty Company
Product Portfolio
Launch two proprietary drugs
Build late stage pipeline
Market Presence
Proprietary product front ends in US, key ROW &
European markets
Market Positioning
Innovation led company
Differentiated branded generic company

GROWTH STRATEGIES TO BRIDGE GAPLicensing

Build differentiated product franchise
Invest in building brands
Expand into new territories
Transition into a proprietary product marketing company

Shareholding Pattern (As on 31-03-2013):

Particulars

% holdings

Promoters
48.27
FIIs
34.92
Indian Financial Inst., Banks, 3.35
Bodies Corporate
1.76
Mutual Funds
1.12
Non Resident Indians
0.56
Resident Individuals
9.28
Others
0.74
Total
100.00
MERGER WITH MOTILAL OSWAL
Investors are recommended to buy the stock for a price
target of Rs565 for medium to long term investment.

CSR ACTIVITIES
CHILD HEALTH:
Niramaya Health Foundation, Mumbai (www.niramaya.org),
Spandan Samaj Sewa Samiti, Khandwa, Madhya Pradesh
SUSTAINABLE LIVELIHOOD:
sustainable livelihood through Skill development courses in Nasik.
Individuals who are disabled are rehabilitated thereby enabling them
to lead productive lives, through Jaipur Foot a renowned NGO.
Employee Volunteering & Medicine donation:
around 1900 employees have offered their support, time and help for
various initiatives. Medicine donation, medical camps, ambulatory
service.

CONCLUSION:
SPECIALITY FORMULATIONS BUSINESS REVENUE,
EXCLUDING OUT-LICENSING,
GREW BY 20.37 % TO RS. 607.41 CR FOR THE QUARTER ENDED
JUNE 30, 2013 FROM RS. 504.64 CR FOR THE CORRESPONDING
PERIOD PREVIOUS FISCAL.

THE COMPANY'S GENERICS BUSINESS ,GREW

TO RS. 624.25 CRORE FROM RS.530 CRORE, A GROWTH OF 17.78 %
WITH US GENERICS BUSINESS GROWING BY 13.91 %....
LOOKING INTO THE PRESENT SCENARIO OF THIS PRODUCT INTO THE
MARKET. THE POSITION OF THIS PRODUCT IN THE MEDIUM ,IT IS NOT
IN THE VERY GOOD POSITION BUT IT HAS THE SCOPE OF BEING IN A
BETTER POSITION. THIS COMPANY WILL SURELY ACHIEVED ITS
DESIRED OBJECTIVES VISION MISSIONS AND TARGETS ,WILL BE IN
THE TOP POSITION OF PHARMACEUTICAL MARKET